Concentra Earnings Call Highlights Growth, Cash Strength

Concentra Group Holdings Parent, Inc. ((CON)) has held its Q4 earnings call. Read on for the main highlights of the call.

Concentra Group Holdings Parent, Inc. struck an upbeat tone on its latest earnings call, underscoring strong operational momentum, healthy double‑digit revenue growth, expanding adjusted EBITDA, and robust free cash flow. Management acknowledged higher leverage, separation costs, and investment spending, but insisted these are transitional headwinds outweighed by the company’s underlying performance.

Revenue Growth — Q4 and Full Year

Concentra posted Q4 2025 revenue of $539.1 million, up 15.9% year over year, with $493.8 million excluding Nova and Pivot, reflecting 6.2% organic growth. For the full year, revenue reached $2.2 billion, a 13.9% increase, while excluding acquisitions sales rose 6.4% and 6.8% on a per‑day basis, underscoring solid but less dramatic core expansion.

Strong Volume Trends

Patient demand remained robust, with total visits per day climbing 9.0% in Q4 to more than 51,000, led by 9.1% growth in workers’ compensation and 9.4% in employer services. Across 2025, visits per day increased 7.7% to above 53,000, though excluding Nova, full‑year visit growth was a more modest 2.2%, indicating acquisitions boosted reported volumes.

Rate Improvements

Pricing also contributed to growth, as revenue per visit rose 3.1% in Q4, powered by a 4.1% increase in workers’ compensation rates and 1.2% in employer services. For the full year, revenue per visit advanced 4.3%, with workers’ compensation up 5.3% and employer services up 2.7%, helping offset cost pressures and supporting margin resilience.

Adjusted EBITDA and Margin Expansion

Profitability improved faster than revenue, with Q4 adjusted EBITDA rising 22.9% to $95.3 million and margins widening by 100 basis points to 17.7%. For 2025, adjusted EBITDA reached $431.9 million, up 14.6% year over year, and the full‑year margin ticked up to 20.0% from 19.8%, signaling better operating leverage despite integration and separation costs.

On‑Site Segment Acceleration

The On‑Site Health Clinics segment delivered standout growth, with Q4 revenue surging 112% to $36.2 million, heavily driven by the Pivot acquisition. Even excluding Pivot, On‑Site organic revenue grew 14.6% year over year in Q4, and for the full year the segment generated $110.2 million, up 72% overall and 11.6% organically, highlighting a strategic growth vector.

Cash Flow and Free Cash Flow Strength

Cash generation remained a key highlight, as Q4 operating cash flow increased to $118.7 million from $93.7 million a year earlier. Free cash flow improved to $98.6 million in Q4 from $77.0 million, while full‑year free cash flow totaled $197.8 million, representing a robust 114% conversion of net income and giving management flexibility amid elevated investment.

Operational Efficiencies

The company continued to squeeze costs out of its model, with cost of services falling to 73.9% of revenue in Q4 from 74.2% and to 71.7% for 2025 versus 72.2% in 2024. Adjusted G&A as a share of Q4 revenue declined to 8.5% from 9.4%, reflecting staffing efficiencies and productivity gains that helped offset the impact of separation‑related expenses.

Commercial and Clinical Validation

Management emphasized clinical and commercial proof points, citing an analysis of more than 550,000 claims between 2020 and 2025 showing Concentra‑treated claims cost 25% less and closed 65 days sooner than those handled by other providers. Patient satisfaction reached record levels, and leadership highlighted successful M&A synergy capture along with a robust de novo and acquisition pipeline to fuel future growth.

Adjusted EPS Decline Despite EBITDA Growth

One blemish was earnings per share, as full‑year adjusted EPS fell to $1.37 in 2025 from $1.48 in 2024 despite higher adjusted EBITDA and adjusted net income. The decline signals that share count changes or other dilution factors weighed on EPS, reminding equity investors that headline profit growth did not fully translate at the per‑share level.

Higher G&A Run‑Rate from Separation

While operational G&A ratios improved in the quarter, full‑year G&A as a percentage of revenue rose to 9.4% from 8.2% as the company absorbed incremental separation and public‑company costs. Adjusted G&A increased more modestly to 8.4% from 8.0%, but management acknowledged that separation from its former parent has elevated the ongoing expense base in the near term.

Heavy Investing and Acquisition Cash Use

The company leaned heavily into growth investments, with total investing cash outflows reaching $414.9 million in 2025, largely driven by $303.3 million of business combinations and $82.3 million of capital expenditures. One‑time Nova integration spending, including more than $2 million in integration costs and roughly $15 million of associated CapEx, temporarily weighed on cash flow timing despite strong underlying generation.

Elevated Leverage and Interest Headwinds

Concentra closed the year with $1.57 billion of total debt and a net leverage ratio of 3.4x, above its long‑term target of about 3.0x, leaving some balance sheet work ahead. Management also flagged that Q1 free cash flow will be seasonally soft and pressured by sizable bond interest payments, amplifying the near‑term drag from higher interest costs.

Organic Growth Moderate Excluding Acquisitions

Stripping out Nova and Pivot, the picture is more measured, with Q4 revenue up 6.2% and full‑year revenue up 6.4% on an organic basis. Visits, excluding acquisitions, rose 2.6% in Q4, underscoring that a meaningful portion of headline growth is currently acquisition‑driven, an important nuance for investors assessing the sustainability of the top‑line trajectory.

Employer Services Rate Mix Headwind

Within employer services, pricing momentum cooled in Q4, as revenue per visit rose just 1.2% compared with stronger gains in workers’ compensation. Management attributed the slowdown to a mix shift toward lower‑ticket drug screens and away from higher‑priced physicals, creating a modest headwind to employer services revenue growth despite firm demand.

State Fee Schedule Constraints

Regulatory economics continue to shape the company’s geographic expansion strategy, with New York a notable example where revised workers’ compensation fee schedules still fall short of Concentra’s hurdle rates. While certain evaluation and management codes saw roughly 50% increases, management said further fee improvements are required before meaningfully entering the state, limiting near‑term growth there.

Increased Financing Costs from Recapitalization

The capital structure reset tied to the July 2024 recapitalization has materially raised cash interest expense, dampening net cash flow even as operating earnings grow. These higher financing costs, combined with temporarily elevated leverage, represent a key financial overhang that management aims to address through disciplined cash deployment and gradual de‑leveraging.

Forward‑Looking Guidance and Outlook

For 2026, Concentra guided to revenue of $2.25 billion to $2.35 billion and adjusted EBITDA of $450 million to $470 million, implying continued growth with an adjusted EBITDA margin around 20%. Plans include 7 to 9 new sites, modest rate and visit gains excluding Nova, $70 million to $80 million of CapEx as Nova integration spend rolls off, free cash flow of $200 million to $225 million, and a move toward roughly 3.0x net leverage by year‑end.

Concentra’s earnings call painted the picture of a company executing well operationally, using acquisitions and on‑site clinics to accelerate growth while steadily improving margins and cash generation. Although higher leverage, separation‑driven G&A, and increased interest costs temper the story, management’s guidance and clinical‑outcome advantages suggest a constructive long‑term setup for investors watching the name.